To the Editor: In her Editorial about disparities in the use of implantable cardioverter-defibrillators (ICDs), Dr Redberg1 raised an important question about which Medicare beneficiaries will benefit from ICDs,
an issue that concerns patients, policy makers, and ICD manufacturers.
The question could be expanded to all individuals at risk of sudden cardiac death who might benefit from ICD implantation, not only Medicare patients. Therefore, the issue should be whether persons who are more likely to develop sudden cardiac death and benefit from ICD therapy as primary prevention can be identified or predicted.
Soliman EZ. Predicting Benefit for Implantable Cardioverter-Defibrillator Use. JAMA. 2008;299(3):286-287. doi:10.1001/jama.299.3.286-b